NASDAQ:RIME 13 February 2026

March 27, 2026, 7:00 AM EDT. Madrigal Pharmaceuticals (MDGL) shares have risen sharply, gaining 14.2% in the past week and 17.9% over the last month, despite a 12.6% decline year-to-date. The company's one-year return stands at 53.8%, buoyed by investor interest in its biotech progress. A Discounted Cash Flow (DCF) analysis estimates Madrigal is approximately 71.6% undervalued relative to its current price of around $518.76 per share, based on projected future cash flows. This valuation suggests significant upside potential. However, the stock carries risk given its volatile short-term movements and biotech sector dynamics. Investors should weigh the valuation score of 4 out of 6 and monitor ongoing developments in the company's financials and pipeline before making decisions.